Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Episode 11: Dr. Jessica Tao, Johns Hopkins University {Baltimore, MD}
Transcript
- 0:002 Great Things that Go Great Together Sounds like a
- 0:03commercial for candy, but a Johns Hopkins researcher is
- 0:06crafting a sweet new earlier detection method for breast
- 0:09cancer, blending A newly developed AI blood testing
- 0:12technique along with the traditional mammogram.
- 0:15The mix may be closer than you think, thanks in part to
- 0:18earlier.org. Isn't that interesting?
- 0:21Here's Martha Kaley, founder and executive directorofearlier.org
- 0:25and earlier detection for breast cancer.
- 0:27This is another wonderful researcher of ours, and her name
- 0:31is Doctor Jesse Tao, and she's from Johns Hopkins, and I'm so
- 0:37proud of her. You have congratulations on all
- 0:41that you have achieved in such a short period of time.
- 0:45She's an assistant professor of oncology there, and she has this
- 0:51most interesting research. I think that it is so promising
- 0:57and it's so developmental. And so I'm going to let you talk
- 1:01about it and then I'm going to ask you questions as I may.
- 1:05I'll probably jump in because I do that.
- 1:07OK. So I'm just going to let you
- 1:09kind of describe maybe how you decided on looking into this and
- 1:16and what your what your thought process were.
- 1:19Well, first of all, thank you so much for the invitation to speak
- 1:23on your podcast and also for the support of earlier.org, which
- 1:29was really instrumental to getting our work and project off
- 1:32of the ground. Right.
- 1:34Great. That's what we try to do, right?
- 1:37Yeah, well, the reasoning and rationale for our work came from
- 1:44really trying to develop better screening tools and methods for
- 1:49breast cancer and being able to detect breast cancer earlier
- 1:55'cause we know that though mammography and biopsy has been
- 1:59a mainstay for breast cancer detection, these tools are not
- 2:03perfect. They're life saving and
- 2:05important, but they're not perfect.
- 2:08We know that sometimes mammograms can miss cancers,
- 2:12especially in women with dense breast tissue or younger women.
- 2:19And on the flip side, the biopsies themselves can
- 2:23sometimes be unnecessary as well, meaning that there can be
- 2:27an abnormality seen on breast imaging.
- 2:31But when radiologists go and biopsy that, it becomes benign.
- 2:36And so that's very stressful, it's painful.
- 2:41So we were really focused on developing a new way to help
- 2:47detect breast cancer in its earlier stages from blood using
- 2:51a blood test. And the type of blood test that
- 2:55we are developing is called Delphi, which is the type of
- 3:00liquid biopsy technology that was developed in labs here at
- 3:05Hopkins and works through type of approach called DNA
- 3:11fragmentation. In simple terms, what that means
- 3:15is that it looks at the size of fragments of DNA that are shed
- 3:20into the bloodstream. So we know that actually all
- 3:24cells and all tissues shed DNA to the into the bloodstream.
- 3:28Healthy tissues sheds DNA dyes and then sheds its DNA into the
- 3:32bloodstream. Tumor cells also shed DNA into
- 3:35the bloodstream. But Delphi uses machine learning
- 3:39to help distinguish between the DNA fragment patterns, the
- 3:45patterns between the sizes of the DNA between healthy
- 3:48individuals and those with cancer.
- 3:51And our vision was to develop a screening program that would use
- 3:57a blood test as an injunctive to normal mammogram and breast
- 4:03imaging, which still, which still remains the gold standard
- 4:06though the blood test, the sorry, the, the mammogram, the
- 4:11breast imaging can have both false positives and false
- 4:13negatives. And so by developing a blood
- 4:17test to be used in conjunction with breast imaging, traditional
- 4:20breast imaging, we were hoping to improve the sensitivity and
- 4:24specificity of detecting a breast cancer.
- 4:28Right. You know, I think talk to me
- 4:30about the Delphi, how long has that technology been available?
- 4:34Is it is it available for in all different places or is it
- 4:38specifically Johns Hopkins? Well, so Delphi is a test that
- 4:44is investigational, meaning that it has been developed initially
- 4:50in other cancer types, including lung and GI cancers.
- 4:55It's not considered part of standard of care because in
- 4:59order for a test to become standard of care, it needs to
- 5:04undergo rigorous clinical testing, clinical validation and
- 5:08clinical trials. And so that was our the purpose
- 5:11of our research in breast cancer.
- 5:13We developed using the seed funds from earlier.org.
- 5:17We developed a study called the early study, which is now IRB
- 5:23approved. And that study is basically a
- 5:27prospective study where we're enrolling women who are
- 5:31undergoing screening mammogram and alongside their screening
- 5:36mammogram, they're getting this blood test called a liquid
- 5:40biopsy. So it's two tubes of blood and
- 5:44using that, the blood collected from the early study, from
- 5:47patients who participated in the early study and then others from
- 5:51healthy controls, meaning women who underwent A mammogram who
- 5:55didn't have ultimately have breast cancer, we're beginning
- 6:00to develop clinical validation of the Delphi assay.
- 6:05So yeah. That's that is that I just think
- 6:08that's really amazing. That is remarkable technology
- 6:12and one of my questions I had thought about was the size of
- 6:16the sample that you had to have. But it but the two tubes of
- 6:21blood is like nothing for to worry about.
- 6:24And then you can, as I learned from reading about your work,
- 6:28how, how you can monitor further with that.
- 6:32And I think that that's so positive for being able to
- 6:36understand the changes. I find it just amazing.
- 6:39It could be with DNA fragmentation.
- 6:42That's just great. It is a very promising type of
- 6:46approach and technology, though it's important to have these
- 6:51types of clinical trials in place.
- 6:53The Delphi approach uses machine learning to train its model
- 7:00because it has to distinguish between healthy individuals and
- 7:05those with cancer, and so by training on more models, the
- 7:10model becomes more sensitive. Right.
- 7:14So is it AI? The part with Delphi is that
- 7:18that's the whole, that's the whole thing with getting all the
- 7:21different logarithms, right. That's exactly.
- 7:25That's develops the algorithm. Exactly.
- 7:28Yeah. Awesome.
- 7:30Yeah. So, so talk about how you're,
- 7:33you're hoping and when this when you think this kind of will
- 7:39evolve, give me a, a kind of a time frame in five years,
- 7:44something like that. We certainly hope, we certainly
- 7:47hope so. I'll say with the the, the
- 7:51study, the prospective study is called the early study.
- 7:56It's open here in two breast imaging sites in the Johns
- 8:01Hopkins network. So one in Baltimore and the
- 8:04other in Baltimore County, which is our Green Spring community
- 8:08site. And our goal is to enroll 500
- 8:12women and men and we are a little over a third of the way
- 8:16there. These things do do take time.
- 8:21In order to talk to me about as you read somewhere in your
- 8:27material that so that y'all, you can monitor if medications or if
- 8:33the part part medications were being effective or if they had
- 8:37lost effectiveness or the monitoring of the medications.
- 8:43Oh, yeah. Thank you.
- 8:44So that's a great point as well that you bring up some.
- 8:47I think there's kind of two separate kinds of liquid biopsy
- 8:52assays or not, or I would say different kinds of liquid biopsy
- 8:55assays, which all fall into the category of doing a blood test
- 8:59to look for. In most cases, it's DNA that's
- 9:03been shed from the tumor cells into the bloodstream and it's
- 9:06trying to pick up on that DNA. So Delphi is designed for early
- 9:12detection of breast cancer. So these are women who don't
- 9:16know they have a diagnosis of breast cancer.
- 9:19We are trying to detect the cancer in the blood earlier.
- 9:23I think what you had mentioned it meaning looking at response
- 9:28to treatment is a slightly different that is called minimal
- 9:33residual disease monitoring. So that is currently in in many
- 9:39cases considered standard of care.
- 9:41So if a particularly for patients who have a diagnosis of
- 9:47metastatic breast cancer, they are receiving liquid biopsies to
- 9:51learn about mutations in the cancer cells themselves.
- 9:56And then following the treatment, we can see the
- 9:59changes in those mutations and even the the drop in the cancer
- 10:05DNA into the bloodstream. So that is a little bit
- 10:08different from the Delphi. In the but, but it's kind of the
- 10:14one step with the other. Is that right?
- 10:16It's like, yeah, yeah, that's right.
- 10:18Yeah, it kind of leads its way. I think that that is so
- 10:22encouraging because you know, so many people by getting on a
- 10:27particular medication, if you can't monitor its effectiveness,
- 10:31that's disappointing and that's, that stops any progress for you.
- 10:37So I think that that that would pay be very beneficial for us
- 10:43all. So I that's why I think your
- 10:46work is just remarkable and, and I'm glad that we could be a part
- 10:52of making that happen for you. This is, this is the work that
- 10:57we do funding research for finding a better method for
- 11:01earlier detection of breast cancer.
- 11:03And these early insights are those things that are going to
- 11:07make a change. And I think that that you are so
- 11:11on the forefront of doing this. So what's your next step?
- 11:16You're going to do the clinical study.
- 11:18Oh, and I know another thing that that came to my mind when
- 11:21you mention about females and males.
- 11:23And that's one of the things that really has troubled me a
- 11:26lot. We have a a dear friend who is,
- 11:30was a big football player and all kinds of things.
- 11:35He's an outdoorsman and he was playing in the pool with his
- 11:39daughters and he felt a mass and he didn't think much about it.
- 11:44He thought it might have been a pulled muscle or something.
- 11:47But he finally went to see about it and it was diagnosed as
- 11:50breast cancer. And he's, he was probably in his
- 11:54maybe early 30s for this. And I thought, golly, you know,
- 12:00men don't have any. They don't even think about it
- 12:03for one thing. And if it could be on a standard
- 12:06panel, blood screening panel, how wonderful would that be for
- 12:09them too? So.
- 12:11So tell me, do you think it would translate for male and
- 12:16female right? I think certainly it could.
- 12:20It could. At the moment the majority of
- 12:23the patients who are have participated in the early study
- 12:27are women. Understandably, since most
- 12:32breast cancers still affect women, the vast majority are
- 12:35still diagnosed. So naturally those who are
- 12:39coming to for breast screening are are women, but that doesn't
- 12:43mean that the technology couldn't apply.
- 12:45It would just need to be trained.
- 12:48So at the moment, you know, we don't have the numbers 'cause
- 12:52there are very, very few male participants in the early study.
- 12:57We don't want the numbers to look for biological differences
- 13:01between men and and women. And probably we would want to if
- 13:05we were to develop the test in men or to be sure that it were
- 13:10applicable in men, we would need to have the the numbers in order
- 13:15to help distinguish the very. So yeah.
- 13:20Well, great. Well, is there anything else
- 13:22that you would like to discuss that I haven't asked you about?
- 13:25Because I again, I just get carried away thinking about this
- 13:29is so, so promising. Thank you for that.
- 13:32Well, no, I just wanted to express our appreciation again
- 13:36for the earlier, for your organization and for earlier.org
- 13:40because so often you know, we have a goal and idea in mind,
- 13:46but it's considered high risk meaning, right, there's not a
- 13:52whole lot of data for it. It's very early on in
- 13:57development and so, but it takes a little bit of resources, seed
- 14:05funding in order to get these types of projects off the
- 14:08ground. And I wanted to see that
- 14:10earlier.org was really, really instrumental in making that
- 14:14happen and enabled us to help contribute to a research
- 14:19coordinator to establish the database to write the IRB and
- 14:24get this study off the ground. And enabled us to then now
- 14:30secure larger grants and research funding based on the
- 14:36work that was in byearlier.org. Because our vision is that we
- 14:43want to have a better test for early detection of breast
- 14:49cancer. Our dream is, you know, somebody
- 14:52shows up for their mammogram or their breast MRI and gets a
- 14:56blood test along with it. Just like you're getting a
- 14:59cholesterol, you're going to the doctor and getting your
- 15:01cholesterol test. And that test is going to help
- 15:05improve the ability to detect breast cancer or to detect that
- 15:11it's not breast cancer and spare some women, some patients,
- 15:16unnecessary breast biopsy. Right.
- 15:19That is wonderful. Well, I appreciate so much your
- 15:23work. And one of our things that we
- 15:26have always said I've got a fabulous medical Advisory Board.
- 15:29I don't I don't select the the grants, but I can't say enough
- 15:35good things about how how diligent they are and how how
- 15:41well informed they are that they can see through.
- 15:45And we feel like that even if it doesn't turn out to be
- 15:50successful, that always that's also a success story because
- 15:55then you know what not to look for or you know how to fine tune
- 15:59it for something different. So so I think that a non
- 16:05successful is still successful. So I appreciate so much your
- 16:09being willing to talk with me and good luck on everything and
- 16:13please stay in touch with us. Thank you so very much, I'm so
- 16:18happy. Thank you.
- 16:20This episode of Isn't That Interesting was made possible
- 16:23thanks to volunteers and donors just like you.
- 16:25It was hosted by Martha Kaley, founderofearlier.org and edited
- 16:30by Liam Mcburney. I'm Valerie Amsterdam, reminding
- 16:33you that for the last 30 years, this is North Carolina based
- 16:37organization has helped fund groundbreaking research all over
- 16:41the world, from molecular imaging to a sensitive blood
- 16:44test for breast cancer. Plain and simple, earlier
- 16:47detection saves lives. And you can help host a
- 16:50fundraising event, make a donation or volunteer your time.
- 16:54You can find us not only on the web, but on Facebook and
- 16:57Instagram too. Let's change the picture of
- 17:00breast cancer together.